A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Peanut allergy immunotherapy (Primary)
- Indications Peanut hypersensitivity
- Focus Registrational; Therapeutic Use
- Acronyms EPITOPE
- Sponsors DBV Technologies
- 07 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2017 Status changed from not yet recruiting to recruiting.
- 10 Jul 2017 New trial record